As of May 21, 2013 2:26 PM - Minimum 20 minute delay.
Webcast Coronado Biosciences First Quarter 2013 Conference Call Wednesday, May 08, 2013 8:30 AM ET
Webcast ROTH 25th Annual Growth Stock Conference Monday, March 18, 2013 3:30 PM ET
Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The Company’s two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors.